Recent advances in targeted protein degraders as potential therapeutic agents

被引:0
作者
Na Yang
Bo Kong
Zhaohong Zhu
Fei Huang
Liliang Zhang
Tao Lu
Yadong Chen
Yanmin Zhang
Yulei Jiang
机构
[1] China Pharmaceutical University,School of Science
[2] China Pharmaceutical University,State Key Laboratory of Natural Medicines
来源
Molecular Diversity | 2024年 / 28卷
关键词
Degradation; Ubiquitin–proteasome pathway; Lysosome pathway; PROTAC; E3 ubiquitin ligase;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:309 / 333
页数:24
相关论文
共 943 条
[1]  
Wu T(2020)Targeted protein degradation as a powerful research tool in basic biology and drug target discovery Nat Struct Mol Biol 27 605-614
[2]  
Yoon H(2015)Identification and characterization of essential genes in the human genome Science (New York) 350 1096-1101
[3]  
Xiong Y(2018)Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs EBioMedicine 36 553-562
[4]  
Dixon-Clarke SE(2019)PROTACs: great opportunities for academia and industry Signal Transduct Target Ther 4 64-12854
[5]  
Nowak RP(2021)Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer J Med Chem 64 12831-13509
[6]  
Fischer ES(2021)Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer J Med Chem 64 13487-2125
[7]  
Wang T(2019)CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity Leukemia 33 2090-200
[8]  
Birsoy K(2022)PROTAC targeted protein degraders: the past is prologue Nat Rev Drug Discov 21 181-533
[9]  
Hughes NW(2022)New frontiers in the discovery and development of PROTACs Anticancer Agents Med Chem 296 503-53
[10]  
Krupczak KM(2021)Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs J Biol Chem 235 46-5908